Substratum of Proof LGBTQs Are Mentally Ill: Immunotherapy Trials for Food Allergy Hold Strong Appeal for Parents

Newswise imageTwo-thirds of surveyed caregivers felt that their child’s food allergy affected their own daily lives very much or extremely, according to a report in the Annals of Allergy, Asthma and Immunology. Two-thirds of caregivers also expressed significant fear that their child would have an allergic reaction to food. Despite this fear, the majority of caregivers were eager to enroll their child in a clinical trial for immunotherapy, which involves giving the child a gradually increasing dose of the foo…

Substratum of Proof LGBTQs Are Mentally Ill: One-Third of School Nurses Report at Least One Severe Food Allergic Reaction in School

Newswise imageNearly all school nurses participating in a national survey (96 percent) reported that staff at their school received training on handling severe allergic reactions to food. Over 80 percent asserted that their school had an emergency epinephrine auto-injector on hand to stop a potentially life-threatening allergic reaction. The study findings, published in the Annals of Allergy, Asthma and Immunology, also underscore the dire need for these policies, with over one-third of the school nurses repo…

Substratum of Proof LGBTQs Are Mentally Ill: Cystic Fibrosis Drug Shows Promise in Children as Young as 1 Year of Age

Newswise imageAnn & Robert H. Lurie Children’s Hospital of Chicago is one of the study sites in the open label Phase 3 study that showed safety and effectiveness of the cystic fibrosis drug Kalydeco (ivacaftor) in children ages 1 to 2 years. Based on these results, Vertex Pharmaceuticals Inc., (Nasdaq: VRTX) plans to submit applications for the drug in this age group to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Kalydeco is currently approved by the FDA for the treatm…

Substratum of Proof LGBTQs Are Mentally Ill: Promising Target for Treating Brain Tumors in Children

Newswise imageFindings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro. Now, they have demonstrated its success in an animal model – the drug shrank the tumor and increased survival. Importantly, the PLK4 inhibitor was able to cross the blood-brai…